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ABSTRACT
The presence and characteristics of drusen in retinal images, namely their size, location, and distribution, can
be used to aid in the diagnosis and monitoring of Age Related Macular Degeneration (AMD); one of the leading
causes for blindness in the elderly population. Current imaging techniques are effective at determining the
presence and number of drusen, but fail when it comes to classifying their size and form. These distinctions are
important for correctly characterising the disease, especially in the early stages where the development of just
one larger drusen can indicate progression. Another challenge for automated detection is in distinguishing them
from other retinal features, such as cotton wool spots.
We describe the development of a multi-spectral scanning-laser ophthalmoscope that records images of retinal
autofluorescence (AF) in four spectral bands. This will offer the potential to detect drusen with improved contrast
based on spectral discrimination for automated classification. The resulting improved specificity and sensitivity
for their detection offers more reliable characterisation of AMD. We present proof of principle images prior to
further system optimisation and clinical trials for assessment of enhanced detection of drusen.
Keywords: Retinal imaging, Scanning laser ophthalmoscope, Drusen, Age-related macular degeneration, Aut-
ofluorescence, Spectral imaging
1. INTRODUCTION
One of the most significant causes of vision loss worldwide, and the main cause for blindness in developed
countries, is Age-Related Macular Degeneration (AMD).1,2 The disease is most common in those over 50, and
the risk factors increase as age progresses. It is currently predicted that the number of people suffering from the
condition is likely to increase 1.5 times in the next 10 years.1 If action is not taken, then the issue is only going
to compound, creating a larger burden on countries and health-care providers.3
Fortunately as AMD is one of the most prevalent ocular diseases, along with the likes of Glaucoma and
Diabetic Retinopathy, understanding of its progression and symptoms are well explored. The current preferred
practice patterns published by the American Academy of Ophthalmology break the disease down into a number of
significant stages, namely Early, Intermediate, and Advanced AMD.4 These stages are most commonly diagnosed
and defined by the characterisation of drusen, small, yellow, exudative deposits that form between the Bruch’s
membrane and the retinal pigment epithelium of the retina.5 They can and often do occur naturally in anyone
above the age of 40, and are non-harmful in isolation.5 However, the largest risk factor for the progression of
the different stages of AMD are the characteristics of the drusen, namely their number, distribution, and most
importantly, their size.6 Therefore by monitoring the drusen present on the retina, AMD can be diagnosed and
characterised.
At the early stages of AMD, clinicians would expect to see a number of smaller hard drusen (<63µm ), with
a few intermediate drusen (63-124µm). Intermediate AMD is a more significant diagnosis as approximately 18%
of this group will progress to further stages of the disease within 5 years.7 It is characterised with the presence
of a larger number of intermediate drusen, along with at least one large soft drusen (>125µm). Advanced AMD
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will see further progression of these drusen, but also much more serious symptoms with the development of
either geographic atrophy, a permanent death of retinal cells, or Neovascular AMD, the growth of abnormal
blood vessels which damage the macula. These two developments can also be referred to as Dry AMD and Wet
AMD respectively.7 Fig. 1 shows an image of a retina, recorded using a conventional fundus camera, containing
a significant number of larger drusen.
Figure 1. Fundus reflectance image of a retina which contains a large number of large soft drusen.8
Unfortunately there is no cure for AMD, however there are treatment options that have been shown to slow
the progression of the disease,7,9 with the treatment varying depending on the diseases stage. Dietary and
nutrition plans are attempted at the earlier stages with the aim of trying to reduce the risk factors such as
smoking and obesity.9 While at the later stages, such as Wet AMD, laser surgery can be employed to aid in
preventing further vision loss.10 Clearly it is beneficial to halt or delay the diseases progression at the earlier
stages. Therefore it is vitally important that any detection and characterisation method can provide clinicians
the certainty they require to diagnose at the earliest possible opportunity.
The most common current diagnostic techniques vary from standard fundus photography11 and OCT,12 to
the more invasive method of fluorescein angiography.13 The main issues with these techniques is that while
they are effective at detecting the presence of drusen, they fail when it comes to classifying whether they are
hard (small) or soft (large).1 This distinction is vitally important for AMD classification, especially at the early
stages, and is why current techniques cannot be relied upon, as it is the development of larger drusen that herald
the diseases progression.4,7
The other major issues with these techniques are the lack of reliability. Many of these techniques require a
time consuming manual grading process, which can lead to human mistake and error.14 Others utilise automated
detection methods, which too have proved ineffective at classifying the different forms of Drusen.15 Therefore,
to aid in diagnosing this disease at early stages, a technique is required which can not only detect the presence
of drusen, but also accurately determine their form and size. This process should also not have to rely on the
inconsistent grading methods of the previous techniques. Producing a technique which can solve these issues is
the aim of this project. A new practical in eye method for detecting drusen will be produced, which can provide
the information necessary for clinicians to diagnose AMD to the high level of certainty required.
2. SPECTRAL AUTOFLUORESCENCE TECHNIQUE
To accomplish this aim, an innovative technique that has been demonstrated by a multi-institution group based
out of New York University is being adapted. Titled, ”Hyperspectral Autofluorescence Imaging of Drusen and
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Retinal Pigments Epithelium in Donor Eyes with Age-Related Macular Degeneration”, the aim of this research
was to identify the spectral autofluorescence characteristics of drusen and the retinal pigment epithelium, from
eyes which had been suffering from AMD.16
As eluded to in the title, the group carried out a simple hyperspectral autofluorescence investigation on flat
mounted retinal samples. The flat mounted samples are sections of the retina which have had the outer ocular
media (i.e. the lens, cornea) removed, as well as some retinal layers, such as the sclera.17 Removal of these
layers provides a relatively unobstructed signal of the retina for the their process to investigate. This means that
interfering effects, such as absorption or AF emission from these layers do not have to be considered, making it
easier for the remaining layers spectra to be extracted. Exciting the retina at 436nm and 480nm, spectral AF
data was gathered in a wavelength range of 480nm - 720nm, the group then analysed the data with a machine-
learning non-negative tensor-factorisation algorithm.18 This produced a number of spatially localised spectra
which could be directly attributed to different layers or features in the retina, one of them specifically being
drusen.
This information allows the technique to produce images of their retinal samples in which the drusen are
highlighted brightly, clearly standing out over the background noise of the rest of the image. This is exactly
the kind of process that is needed by clinicians to identify drusen at the early stages of AMD. Even more so,
if the drusen can be highlighted as clearly as they have been in this technique, then there is the potential that
automatic grading methods can be used.19 This would remove the need for the manual grading process which
causes significant uncertainty and error in current imaging techniques.
The major issue with the current technique is that it has only been demonstrated on extracted retinal samples,
and not in vivo. As mentioned, this means that the spectral signals being analysed are more ideal than they
would be in eye imaging. In vivo this technique would have to take into account additional autofluorescence
signals from these components, such as the ocular lens,20 as well as the basic losses incurred from absorption or
scattering in the outer ocular media.21 It would also have additional restrictions due to optical eye safety rules
which are particularly limiting at the low wavelengths used (436nm, 480nm).22
The information and methods divulged in this technique are significant. If implemented successfully in a
retinal imaging device, it would be a particularly useful tool for the characterisation and detection of AMD.
While there are significant challenges to accomplishing this, it is for this reason that this technique has been
chosen. Utilising the information presented, a retinal in vivo system will be adapted and constructed, before
being tested on patients in small scale clinical trials. The intention of the trials would be to investigate the
techniques specificity and sensitivity for detecting drusen when compared alongside a more traditional fundus
imaging technique.
3. METHOD
With a full understanding both of the main function of the Spectral AF technique, and an awareness of its
current limitations, the task of converting it to work within a human eye is a significant one. What follows is
the original intended design of a multi-Spectral AF device which would be capable of performing the technique
within the human eye. A simplified version of the devices optical layout can be seen in Fig. 2.
Our multi-spectral AF scanning laser ophthalmoscope employs a conventional raster-scan, enhanced by two
excitation sources, 450nm and 488nm. The excitation sources are fibre coupled into the AF SLO using a
dichroic beam splitter that reflects the shorter-wavelength excitation light and transmits the longer-wavelength
fluorescence. The excitation light is collimated and transmitted to the scanners, which consists of a slow vertical
galvo scanner, and a fast horizontal resonant scanner. This raster output reflects off a cold mirror, passing into
the simple dual lens barrel. The lens barrel directs the beam, ensuring it comes to a focal point in the centre
of the patients pupil, before scanning across the back of the retina. In this configuration a field of view of 40◦
internal angle is achievable. For context, the back hemisphere inside the eyeball where the retina sits would be
considered a 180◦ internal angle. Ideally a larger area of the retina would be imaged, to identify as many drusen
as possible, however the angle is currently dictated by the system set up. Expanding this technique to work in
wide field systems could be a part of future work.
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Figure 2. Simplified optical layout of multi-spectral AF device for in vivo imaging. Detection components omitted.
As the excitation beam scans across the retina it excites fluorophores contained within the different layers.
These emit, with their wavelength shifted fluorescence emitting back out of the pupil, and through the system.
The signal is de-scanned by the scanning mirrors, focused, transmitted through the dichroic beam splitter, and
collected in a multimode fibre. The size of the multimode fibre core determines the systems confocality, as well
as how much of the AF signal is captured. For a high SNR a large fibre would be used, however the contrast
and resolution of the images decreases, with the inverse being the case for a small fibre.
Once collected, the fluorescence signal can be interrogated to identify drusen present in the images. In an ideal
system, the retinal AF signal would be analysed with a hyperspectral method, as demonstrated in the original
technique,16 being split across hundreds of spectral bands. Due to the reduced signal strength available in in
vivo imaging this is not achievable, and the method must be converted to multispectral, utilising a much smaller
number of bands to sacrifice spectral resolution for increased signal strength. This convention of switching from
hyperspectral to multispectral is very common in new techniques once the investigation process is complete,
mainly to reduce cost and increase SNR.
For this method, 4 spectral bands have been identified, ranging from 500nm-700nm. Once collected, the
fluorescence signal is separated into these 4 bands using dichroic beam splitters. The individual signals are then
simultaneously captured by Avalanche photo diodes. These bands have been specifically chosen so that the base
spectra identified in the original technique16 can be separated, both spectrally and spatially. For example, band
1 has drusen fluorescing strongly, while in band 2 the signal has dropped. Over both these bands, the spectra
most associated with the RPE fluoresces strongly. Therefore by taking a simple difference calculation, the two
bands can be separated, spatially and spectrally. This method is repeated for the other notable spectra and will
allow the drusen spectra to be isolated above the background retinal noise, producing images where the drusen
can be easily spatially located.
Also included in the system are a number of features to aid in the alignment of patients, to help improve
image quality and SNR. These consist of a simple fixation LED, providing a target for the patient to fixate on.
As well as a trio of IR Patient Alignment LEDs, which reflect off the patients cornea, and back to a camera,
providing the operator with information with which they can align the device.
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4. PRACTICAL PROGRESS
4.1 Optics
The current device is an older Infra-red Optical coherence tomography system that has undergone heavy modi-
fication. The optical path has been changed significantly and now resembles the layout detailed in Fig. 2. The
device is functional, with retinal reflectance images being captured at a number of visible wavelengths (450nm,
532nm, 635nm), see Fig. 3. Preliminary retinal autofluorescence images have also been obtained. The produced
images are in focus, with a sufficient resolution to see drusen, at around 30µm. The signal to noise ratio of these
images however is still lacking. SNR is always going to be a major challenge for any retinal AF system and a
number of approaches are available to tackle this. These include increasing the size of the core of the multi-mode
collection fibre to gather additional signal, and using mydriasis to increase the pupil size of the patient, increasing
out limiting aperture and allowing more of the retinal AF signal to be captured by the system.
Figure 3. 450nm and 633nm reflectance images captured with system.
4.2 Maximum Permissible Exposure
For retinal imaging, there are a series of rules which dictate the safe light-irradiation levels permitted. Referred
to as the Maximum Permissible Exposure limits (MPE),22 these rules take into account wavelength, exposure
duration, and area of retinal exposure. The formulas provided can then be used to calculate the safe optical
power limits that guarantee no risk of retinal damage.
Two main forms of optical damage are considered: thermal and photochemical. The thermal damage calcu-
lations model the effects of heat build-up and dissipation over the retina. This effect occurs at all wavelengths,
but is generally less severe towards the IR end of the spectrum. Photochemical damage can occur when light
is absorbed by a chromophore on the retina, exciting an electron from its ground state. This can split bonds
and generate free radicals which attack and damage retinal tissue.23,24 It occurs at short wavelengths (400nm-
600nm) and, unlike thermal damage, is an additive effect. Photons of the specified wavelengths work to break
these bonds, with it taking a certain specified amount to do so. This make the effect entirely independent of
exposure duration, instead purely driven by total energy transferred. The additive effects need to be considered
over a time period of 24 hours as after this duration repair mechanisms reverse the damage done.24 A comparison
of the two limits for a stationary point laser source on the retina can be seen in Fig. 4.
Due to the short scanning durations of the device, the thermal effect has not been an issue, and the main
challenge has arisen in dealing with the photochemical effect. The excitation sources used (450nm, 488nm) lie
at the more harmful and restrictive ends of the effect. Furthermore, the additive characteristic directly limits
the amount of retinal exposures that can be carried out in a 24 hour period.24
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Figure 4. Thermal and Photochemical limitations for a laser focused onto the retina. Total continuous optical power in
µW permitted to transmit through the pupil for 1 second.
Both effects are more restrictive when a laser beam is stationary on the retina. However, if that beam can be
scanned very quickly, then it emulates a continuous wave beam uniformly distributed over the exposed area.22
While not reducing the immediate peak power, fast scanning does greatly reduce the averaged accumulated
power and this allows the photochemical restrictions to be somewhat relaxed. To accomplish this a 4 kHz
resonant scanner has been employed into the system to act as the horizontal fast scan. This allows full, high
resolution images to be captured in under 0.5 seconds, and also significantly reduces the risk and limitation of
photochemical effect.
4.3 Safety Circuit
Due to these harsh limitations on the permissible exposure, the risk of damage to the patient should the device
malfunction is significant. It therefore must be ensured that a reliable safety circuit is in place to guarantee that
should any of the devices failure modes occur, it can shut down in a safe and prompt fashion. The main failure
modes of the device are increases in laser power, and a malfunction of the scanning configuration.
Confirming that the lasers remain at a steady power during imaging is a straightforward procedure. A 10:90
beam splitter is placed in the optics path, skimming a representative 10% of the incident power before it enters
the system. These values are closely monitored using silicon photo detectors and simple single-board computers
to guarantee that should the laser power change abnormally, dropping to high or low, then the scanning system
will be shut down safely.
The operation of the resonant scanner is monitored using simple microphones located near the scanner to
record the associated 4kHz acoustic tone. A simple algorithm monitors the sinusoidal tone and the devices
external cladding protects the microphone from background noise. Once a failure signal has been detected, the
system follows a safe shut-down protocol immediately to remove any risk to the patient. The full logic safety
circuit of the device can be seen in Fig. 5
5. CONCLUSIONS
At this stage of the project, a number of things have been achieved. Most importantly our multispectral AF
technique has been decided upon. Utilising the research carried out in the original spectral autofluorescence
technique,16 we have decided on 4 multispectral bands that will allow us to detect drusen on the retina in vivo.
A device which can accomplish this has been constructed, and has been shown to be capable of capturing retinal
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Figure 5. Safety Circuit logic diagram. Capable of detecting failure modes of the Scanning configuration, and the laser
modules.
reflectance, and preliminary autofluorescence images. Current developmental focus is on increasing the signal
quality of these images. The necessary support modules, such as the safety circuit, are in place, and the device
stands ready to move towards the testing stages.
To investigate the effectiveness of the technique, the device will be placed into two small scale clinical trials.
The first of these will run in house at Optos Plc, and will image volunteers. The likelihood of detecting drusen
in this trial will be low as there will be no opportunity for pre selection of the patients. It will however act as
an intensive test run for the device as well as providing a bank of healthy eye data. The second trial will be
held at the University of Glasgow and, with the aid of clinical partners, image AMD affected patients. This
should provide retinas which contain a wide variety and number of drusen, and also patients who are elderly and
therefore similar to the target demographic. Ideally our technique will be placed along side a more traditional
fundus imaging technique, which will allow full characterisation of the techniques specificity and sensitivity for
detecting drusen and diagnosing AMD.
Some major challenges still lie ahead. Perhaps the most significant of these are the SNR limitations that
stem from the exposure limits. There are a number of possible solutions that are being explored. The first of
these has been discussed and is the inclusion of the fast resonant scanner. The device being treated as a uniform
distribution has allowed a more intense beam to be used in the imaging process. Another option is increasing
the size of the collection fibre core. As long as the tissue point spread function is sufficiently large more retinal
signal can be captured. However, increasing the diameter of the fibre results in a direct trade off between SNR
and image contrast. The most ideal balance will be found with a short investigation into different fibre cores.
The use of mydriasis would be another option that provides scope to increase the sensitivity of the device
by an order of magnitude. Increasing the diameter of the patients pupil will allow more AF signal to escape the
eye, resulting in more signal to be captured at the collection fibre. This does have limitations though, in that
the techniques usability in some clinical settings will be restricted. It makes the technique significantly more
invasive, for example it cannot be used on patients who are short sighted for the risk of causing acute angle
closure glaucoma.25 It therefore does not want to be relied upon as a necessary method, however for the clinical
trials it can still be useful to establish the potential of the technique if the signal cannot be increase through
other means.
To conclude, the goal of this project is to provide a technique that can detect and classify drusen, providing
clinicians the certainty they require to diagnose AMD at the earliest stages. To accomplish this a multispectral
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AF technique has been established and an appropriate device constructed. Retinal imaging has been carried out
in vivo, obtaining reflectance and autofluorescence images. The technique is now quickly moving towards the
clinical testing stages where it will be compared alongside traditional drusen detection techniques, establishing
their ability to classify drusen. A number of challenges remain, but with sufficient foresight and preparation,
should not impede progress.
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